)
Visual
test
Annexin Pharmaceuticals
Annexin Pharmaceuticals (ANNX) investor relations material
Annexin Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary5 Feb, 2026
Executive summary
Achieved key milestone with first patients dosed in phase 2a study for ANXV in diabetic retinopathy (DR) and retinal vein occlusion (RVO), with initial results deemed favorable and no safety concerns observed.
Focused on expanding clinical data in DR and RVO to attract potential licensing partners and support future financing.
Cost-saving measures and delayed activities extended cash runway to June 2026.
Financial highlights
Net loss for Q4 2025 was -10,515 TSEK, improved from -12,350 TSEK year-over-year; full-year net loss was -36,893 TSEK, improved from -50,252 TSEK.
Operating loss for Q4 was -10,746 TSEK (vs. -12,630 TSEK); full-year operating loss was -37,358 TSEK (vs. -50,480 TSEK).
Cash flow from operations for the year was -36,925 TSEK (vs. -50,228 TSEK); year-end cash position was 27,395 TSEK (vs. 16,337 TSEK).
Equity per share at year-end was 3.77 SEK (vs. 4.29 SEK); EPS for the year was -5.58 SEK (vs. -11.11 SEK).
Solid equity ratio of 83% at year-end (vs. 72%).
Outlook and guidance
Financing secured through June 2026 following a 50 MSEK rights issue and cost-saving initiatives.
Ongoing evaluation of additional financing options to support continued operations and clinical development.
No dividend proposed for 2025.
Future funding strategy beyond June 2026
Impact of initial DR/RVO results on study design?
Ophthalmology focus: impact on licensing timeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position.
Next Annexin Pharmaceuticals earnings date
Q1 202612 May, 2026
Annexin Pharmaceuticals
Next Annexin Pharmaceuticals earnings date
Q1 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Annexin Pharmaceuticals AB is a Swedish biotechnology company focused on developing innovative therapies for cardiovascular and inflammatory diseases. Its lead product, ANXV, is a recombinant human protein, Annexin A5, which has the potential to treat conditions related to blood vessel damage and inflammation. The drug is currently undergoing clinical trials, particularly for Retinal Vein Occlusion (RVO), a condition that can lead to vision loss, and shows potential for broader applications, including in oncology. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage